Waldenstrom Macroglobulinemia - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 156 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Waldenstrom Macroglobulinemia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Waldenstrom Macroglobulinemia - Pipeline Review, H2 2014', provides an overview of the Waldenstrom Macroglobulinemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Waldenstrom Macroglobulinemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Waldenstrom Macroglobulinemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Waldenstrom Macroglobulinemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Waldenstrom Macroglobulinemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Waldenstrom Macroglobulinemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Waldenstrom Macroglobulinemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Waldenstrom Macroglobulinemia Overview 9
Therapeutics Development 10
Pipeline Products for Waldenstrom Macroglobulinemia - Overview 10
Pipeline Products for Waldenstrom Macroglobulinemia - Comparative Analysis 11
Waldenstrom Macroglobulinemia - Therapeutics under Development by Companies 12
Waldenstrom Macroglobulinemia - Therapeutics under Investigation by Universities/Institutes 14
Waldenstrom Macroglobulinemia - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Waldenstrom Macroglobulinemia - Products under Development by Companies 18
Waldenstrom Macroglobulinemia - Products under Investigation by Universities/Institutes 19
Waldenstrom Macroglobulinemia - Companies Involved in Therapeutics Development 20
Gilead Sciences, Inc. 20
Millennium Pharmaceuticals, Inc. 21
Novartis AG 22
Genmab A/S 23
Celgene Corporation 24
Onyx Pharmaceuticals, Inc. 25
Bayer AG 26
Incyte Corporation 27
Idera Pharmaceuticals, Inc. 28
Pharmacyclics, Inc. 29
Onconova Therapeutics, Inc. 30
Immune System Therapeutics Ltd. 31
arGEN-X BV 32
Karyopharm Therapeutics, Inc. 33
AbbVie Inc. 34
Waldenstrom Macroglobulinemia - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Combination Products 36
Assessment by Target 37
Assessment by Mechanism of Action 40
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
ibrutinib - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
carfilzomib - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
oprozomib - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
everolimus - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
idelalisib - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
copanlisib - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
ofatumumab - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
GS-9973 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
ARGX-110 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
IMO-8400 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
pevonedistat hydrochloride - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
rigosertib sodium - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
MLN-0128 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
NSC-678515 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
spebrutinib besylate - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
venetoclax - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
selinexor - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
INCB-40093 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
ACP-196 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
INCB-40093 + INCB-39110 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
IST-1097 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
FV-162 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
FV-214 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Waldenstrom Macroglobulinemia - Recent Pipeline Updates 98
Waldenstrom Macroglobulinemia - Dormant Projects 145
Waldenstrom Macroglobulinemia - Discontinued Products 146
Waldenstrom Macroglobulinemia - Product Development Milestones 147
Featured News & Press Releases 147
Jun 10, 2014: arGEN-X and The Leukemia & Lymphoma Society Partner on the Development of ARGX-110 for the Treatment of Waldenstr�m's Macroglobulinemia 147
Dec 04, 2013: Idera Pharmaceuticals Opens Enrollment for Phase 1/2 Clinical Trial of IMO-8400 in Waldenstr�m's Macroglobulinemia 147
Nov 07, 2013: Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations On Oprozomib at 55th American Society of Hematology Annual Meeting 148
Jun 20, 2013: Pharmacyclics Presents Ibrutinib Monotherapy Clinical Trial Data In Patients With Waldenstrom's Macroglobulinemia At ICML 149
Apr 01, 2013: Onyx Pharma To Present Data On Oprozomib At 14th International Myeloma Workshop 150
Feb 12, 2013: Janssen Announces FDA Grants Two Oncology Breakthrough Therapy Designations For Ibrutinib 150
Dec 06, 2012: TG Therapeutics To Present Clinical Data On Ublituximab At 54th American Society Of Hematology Meeting 151
Nov 06, 2012: Onyx Pharma Announces Data Presentations On Oprozomib At 54th American Society Of Hematology Annual Meeting 152
Nov 08, 2011: Genmab To Present Data On Ofatumumab At 53rd American Society Of Hematology Annual Meeting And Exposition 152
Nov 07, 2011: Pharmacyclics Reports Multiple PCI-32765 Presentations At 53rd American Society Of Hematology Annual Meeting 153
Appendix 155
Methodology 155
Coverage 155
Secondary Research 155
Primary Research 155
Expert Panel Validation 155
Contact Us 156
Disclaimer 156

List of Tables
Number of Products under Development for Waldenstrom Macroglobulinemia, H2 2014 10
Number of Products under Development for Waldenstrom Macroglobulinemia - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Waldenstrom Macroglobulinemia - Pipeline by Gilead Sciences, Inc., H2 2014 20
Waldenstrom Macroglobulinemia - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 21
Waldenstrom Macroglobulinemia - Pipeline by Novartis AG, H2 2014 22
Waldenstrom Macroglobulinemia - Pipeline by Genmab A/S, H2 2014 23
Waldenstrom Macroglobulinemia - Pipeline by Celgene Corporation, H2 2014 24
Waldenstrom Macroglobulinemia - Pipeline by Onyx Pharmaceuticals, Inc., H2 2014 25
Waldenstrom Macroglobulinemia - Pipeline by Bayer AG, H2 2014 26
Waldenstrom Macroglobulinemia - Pipeline by Incyte Corporation, H2 2014 27
Waldenstrom Macroglobulinemia - Pipeline by Idera Pharmaceuticals, Inc., H2 2014 28
Waldenstrom Macroglobulinemia - Pipeline by Pharmacyclics, Inc., H2 2014 29
Waldenstrom Macroglobulinemia - Pipeline by Onconova Therapeutics, Inc., H2 2014 30
Waldenstrom Macroglobulinemia - Pipeline by Immune System Therapeutics Ltd., H2 2014 31
Waldenstrom Macroglobulinemia - Pipeline by arGEN-X BV., H2 2014 32
Waldenstrom Macroglobulinemia - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 33
Waldenstrom Macroglobulinemia - Pipeline by AbbVie Inc., H2 2014 34
Assessment by Monotherapy Products, H2 2014 35
Assessment by Combination Products, H2 2014 36
Number of Products by Stage and Target, H2 2014 39
Number of Products by Stage and Mechanism of Action, H2 2014 42
Number of Products by Stage and Route of Administration, H2 2014 44
Number of Products by Stage and Molecule Type, H2 2014 46
Waldenstrom Macroglobulinemia Therapeutics - Recent Pipeline Updates, H2 2014 98
Waldenstrom Macroglobulinemia - Dormant Projects, H2 2014 145
Waldenstrom Macroglobulinemia - Discontinued Products, H2 2014 146